Hypoxia as a biomarker for radioresistant cancer stem cells

International Journal of Radiation Biology

Volumn 90, Issue 8, 2014, Pages 636-652

  Peitzsch, Claudia ^a   Perrin, Rosalind ^c   Hill, Richard P ^d   Dubrovska, Anna ^a,b   Kurth, Ina ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarker; Cancer stem cells; Hypoxia; Radioresistance

Indexed keywords

HYPOXIA INDUCIBLE FACTOR;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; HUMAN; HYPOXIA; METABOLISM; METASTASIS; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; STEM CELL NICHE;

BIOMARKER; CANCER STEM CELLS; HYPOXIA; RADIORESISTANCE;

ANIMALS; CELL HYPOXIA; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; STEM CELL NICHE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905399609     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2014.916841     Document Type: Article

References (218)

1. Abolmaali N, Haase R, Koch A, Zips D, Steinbach J, Baumann M, Kotzerke J, Zöphel, K. 2011. Two or four hour [ 1 ?F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 50: 22-27.
2. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert J-M, Burger A, et al. 2005. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 8: 131-141.
3. Adams GB, Scadden DT. 2006. The hematopoietic stem cell in its place. Nat Immunol 7: 333-337.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
5. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang J, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, et al. 2011. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science 334: 1278-1283.
6. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pa hlman S. 2005. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16: 554-563.
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006a. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
8. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. 2006b. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848.
9. Bell EL, Emerling BM, Chandel NS. 2005. Mitochondrial regulation of oxygen sensing. Mitochondrion 5: 322-332.
10. Bennewith KL, Dedhar S. 2011. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11: 504.
11. Berra E, Roux D, Richard DE, Pouysségur J. 2001. Hypoxia-inducible factor-1 α (HIF-1 α ) escapes O2-driven proteasomal degradation irrespective of its subcellular localization: Nucleus or cytoplasm. EMBO Rep 2: 615-620.
12. Berra E, Benizri E, Ginouvés A, Volmat V, Roux D, Pouysségur J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steadystate levels of HIF-1 α in normoxia. EMBO J 22: 4082-4090.
13. Bertout JA, Patel SA, Simon MC. 2008. The impact of O 2 availability on human cancer. Nat Rev Cancer 8: 967-975.
14. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. 2004. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24: 8504-8518.
15. Bollineni VR, Kerner GSMA, Pruim J, Steenbakkers RJHM, Wiegman EM, Koole MJB, de Groot EH, Willemsen ATM, Luurtsema G, Widder J, et al. 2013. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med 54: 1175-1180.
16. Bristow RG, Hill RP. 2008. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192.
17. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943.
18. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. 1997. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289.
19. Brown JM, Giaccia AJ. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416.
20. Carroll VA, Ashcroft M. 2006. Role of hypoxia-inducible factor (HIF)-1 α versus HIF-2 α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von hippel-lindau function: Implications for targeting the HIF pathway. Cancer Res 66: 6264-6270.
21. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT. 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing. J Biol Chem 275: 25130-25138.
22. Chapman JD. 1979. Hypoxic sensitizers-implications for radiation therapy. N Engl J Med 301: 1429-1432.
23. Chapman JD, Franko AJ, Sharplin J. 1981. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 43: 546-550.
24. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, et al. 2003. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 162: 1283-1291.
25. Choi Y, Kim HS, Cho K-W, Lee K-M, Yi YJ, Eun S-J, Kim HJ, Woo J, Choi SH, Whangbo T-K, et al. 2013. Noninvasive identification of viable cell populations in docetaxel-treated breast tumors using ferritin-based magnetic resonance imaging. PLoS One 8: e52931.
26. Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, Ménard C, Haider MA. 2009. Comparing oxygen-sensitive MRI (BOLD R2 z.ast; ) with oxygen electrode measurements: A pilot study in men with prostate cancer. Int J Radiat Biol 85: 805-813.
27. Christian N, Lee JA, Bol A, De Bast M, Jordan B, Grégoire V. 2009. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 91: 101-106.
28. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008a. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186.
29. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. 2008b. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
30. Chua YL, Dufour E, Dassa EP, Rustin P, Jacobs HT, Taylor CT, Hagen T. 2010. Stabilization of hypoxia-inducible factor-1 α protein in hypoxia occurs independently of mitochondrial reactive oxygen species production . J Biol Chem 285: 31277-31284.
31. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. 2002. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394.
32. Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, Migliore C, Giordano S, Chiarugi P. 2011. HIF-1? stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51: 893-904.
33. Cooper RA, Carrington BM, Loncaster JA, Todd SM, Davidson SE, Logue JP, Luthra AD, Jones AP, Stratford I, Hunter RD, et al. 2000. Tumour oxygenation levels correlate with dynamic contrastenhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57: 53-59.
34. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. 1998. A new role for hypoxia in tumor progression: Induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2: 259-265.
35. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu C-J, Labosky PA, Simon MC, Keith B. 2006. HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570.
36. Cullis PM, Jones GD, Symons MC, Lea JS. 1987. Electron transfer from protein to DNA in irradiated chromatin. Nature 330: 773-774.
37. Dang CV. 2012. Links between metabolism and cancer. Genes Dev 26: 877-890.
38. Diehn M, Clarke MF. 2006. Cancer stem cells and radiotherapy: New insights into tumor radioresistance. J Natl Cancer Inst 98: 1755-1757.
39. Ding W-X, Yin X-M. 2012. Mitophagy: Mechanisms, pathophysiological roles, and analysis. Biol Chem 393: 547-564.
40. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. 2009. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18) F-FDG PET, (18)F- fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 50: 1020-1027.
41. Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JHM, Lisec J, Lenze D, Gerhardt A, Schleicher K, et al. 2013. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501: 421-425.
42. Dubois LJ, Lieuwes NG, Janssen MHM, Peeters WJM, Windhorst AD, Walsh JC, Kolb HC, Ollers MC, Bussink J, van Dongen GAMS, et al. 2011. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci USA 108: 14620-14625.
43. Duester G. 2008. Retinoic acid synthesis and signaling during early organogenesis. Cell 134: 921-931.
44. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
45. Ellingsen C, Egeland TAM, Galappathi K, Rofstad EK. 2010. Dynamic contrast-enhanced magnetic resonance imaging of human cervical carcinoma xenografts: Pharmacokinetic analysis and correlation to tumor histomorphology. Radiother Oncol 97: 217-224.
46. Ellingsen C, Walenta S, Hompland T, Mueller-Klieser W, Rofstad EK. 2013. The microenvironment of cervical carcinoma xenografts: Associations with lymph node metastasis and its assessment by DCE-MRI. Transl Oncol 6: 607-617.
47. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
48. Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. 2005. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling . Mol Cell Biol 25: 4853-4862.
49. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le Q-T, Chi J-TA, Jeffrey SS, Giaccia AJ. 2006. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226.
50. Eschmann SM, Paulsen F, Bedeshem C, Machulla H-J, Hehr T, Bamberg M, Bares R. 2007. Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of headand-neck cancer. Radiother Oncol 83: 406-410.
51. Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla H-J, Bares R. 2005. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46: 253-260.
52. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. 2005. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337.
53. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P. 2012. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 72: 5130-5140.
54. Finkel T. 2011. Signal transduction by reactive oxygen species. J Cell Biol 194: 7-15.
55. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, et al. 2007. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812-3819.
56. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS. 2009. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69: 7243-7251.
57. Fraga A, Ribeiro R, Príncipe P, Lobato C, Pina F, Maurício J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Rui Medeiros. 2014. The HIF1A functional genetic polymorphism at locus 1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer 50: 359-365.
58. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. 2002. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20: 680-687.
59. Fyles A, Milosevic M, Pintilie M, Syed A, Levin W, Manchul L, Hill RP. 2006. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 80: 132-137.
60. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, et al. 1998. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48: 149-156.
61. Giannoni E, Parri M, Chiarugi P. 2012. EMT and oxidative stress: A bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal 16: 1248-1263.
62. Gillies RJ, Robey I, Gatenby RA. 2008. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49: 24S-42S.
63. Goldberg MA, Dunning SP, Bunn HF. 1988. Regulation of the erythropoietin gene: Evidence that the oxygen sensor is a heme protein. Science 242: 1412-1415.
64. Gordan JD, Bertout JA, Hu C-J, Diehl JA, Simon MC. 2007. HIF-2 α promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 11: 335-347.
65. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. 1953. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648.
66. Grönroos T, Bentzen L, Marjamäki P, Murata R, Horsman MR, Keiding S, Eskola O, Haaparanta M, Minn H, Solin O. 2004. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 31: 513-520.
67. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, OConnor KL, Gao T, et al. 2011. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71: 3246-3256.
68. Gulliksrud K, Ovreb ø KM, Mathiesen B, Rofstad EK. 2011. Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 98: 360-364.
69. Gupta GP, Massagué J. 2006. Cancer metastasis: Building a framework. Cell 127: 679-695.
70. Guzy RD, Schumacker PT. 2006. Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91: 807-819.
71. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
72. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation . Cell 144: 646-674.
73. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, et al. 2013. Oncogenic BRAF regulates oxidative metabolism via PGC1? and MITF. Cancer Cell 23: 302-315.
74. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, et al. 2012. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 3: 783.
75. Harrison L, Blackwell K. 2004. Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl. 5): 31-40.
76. Havelund BM, Holdgaard PC, Rafaelsen SR, Mortensen LS, Theil J, Bender D, Pløen J, Spindler K-LG, Jakobsen A. 2013. Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun 34: 155-161.
77. Heiden MGV, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
78. Helczynska K, Kronblad A, Jögi A, Nilsson E, Beckman S, Landberg G, Pa hlman S. 2003. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 63: 1441-1444.
79. Helleday T, Lo J, van Gent DC, Engelward BP. 2007. DNA double-strand break repair: From mechanistic understanding to cancer treatment. DNA Repair 6: 923-935.
80. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. 2006. Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369-1375.
81. Hirota K, Semenza GL. 2001. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276: 21166-21172.
82. Holmquist L, Jögi A, Pa hlman S. 2005. Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer 116: 218-225.
83. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, et al. 2006. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423.
84. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. 2012. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9: 674-687.
85. Hoskin PJ, Carnell DM, Taylor NJ, Smith RE, Stirling JJ, Daley FM, Saunders MI, Bentzen SM, Collins DJ, d Arcy JA, et al. 2007. Hypoxia in prostate cancer: Correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 68: 1065-1071.
86. Hu S, Wilson KD, Ghosh Z, Han L, Wang Y, Lan F, Ransohoff KJ, Burridge P, Wu JC. 2013. MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells 31: 259-268.
87. Huang S-D, Yuan Y, Tang H, Liu X-H, Fu C-G, Cheng H-Z, Bi J-W, Yu Y-W, Gong D-J, Zhang W, et al. 2013. Tumor cells positive and negative for the common cancer stem cell markers are capable of initiating tumor growth and generating both progenies. PLoS One 8: e54579.
88. Ikeda J, Mamat S, Tian T, Wang Y, Luo W, Rahadiani N, Aozasa K, Morii E. 2012. Reactive oxygen species and aldehyde dehydrogenase activity in Hodgkin lymphoma cells. Lab Invest 92: 606-614.
89. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, et al. 1998. Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1 α . Genes Dev 12: 149-162.
90. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O 2-regulated prolyl hydroxylation. Science 292: 468-472.
91. Jögi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pa hlman S. 2002. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 99: 7021-7026.
92. Jones RG, Thompson CB. 2009. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 23: 537-548.
93. Jordan BF, Magat J, Colliez F, Ozel E, Fruytier A-C, Marchand V, Mignion L, Gallez B. 2013. Application of MOBILE (mapping of oxygen by imaging lipids relaxation enhancement) to study variations in tumor oxygenation. Adv Exp Med Biol 789: 281-288.
94. Kallio PJ. 1998. Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 17: 6573-6586.
95. Keith B, Simon MC. 2007. Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472.
96. Keith B, Johnson RS, Simon MC. 2012. HIF1 α and HIF2 α : Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
97. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori S, Tona Y, Yamazaki H, Naito Y, Senda M. 2011. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 25: 625-633.
98. Kim J, Tchernyshyov I, Semenza GL, Dang CV. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
99. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. 2010. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120: 694-705.
100. Klimova T, Chandel NS. 2008. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 15: 660-666.
101. Koh MY, Lemos R, Liu X, Powis G. 2011. The hypoxia-associated factor switches cells from HIF-1-to HIF-2-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71: 4015-4027.
102. Koppenol WH, Bounds PL, Dang CV. 2011. Otto Warburg s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337.
103. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. 2006. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role for tumor-associated stroma. Cancer Res 66: 632-637.
104. Kroemer G, Pouyssegur J. 2008. Tumor cell metabolism: Cancer s Achilles Heel. Cancer Cell 13: 472-482.
105. Krohn KA, Link JM, Mason RP. 2008. Molecular imaging of hypoxia. J Nucl Med 49(Suppl. 2): 129S-148S.
106. Kumareswaran R, Ludkovski O, Meng A, Sykes J, Pintilie M, Bristow RG. 2012. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci 125: 189-199.
107. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. 2000. Suppression of tumor growth through disruption of hypoxia-inducible transcription . Nat Med 6: 1335-1340.
108. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
109. Le Q-T, Loo BW, Lee N. 2010. Hypoxia imaging for image-guided radiotherapy. In: Tamaki N, Kuge Y, editors, Molecular Imaging for Integrated Medical Therapy and Drug Development. Japan: Springer. pp. 7-18.
110. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al. 2009. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
111. Lin J-L, Wang MJ, Lee D, Liang C-C, Lin S. 2008. Hypoxia-inducible factor-1alpha regulates matrix metalloproteinase-1 activity in human bone marrow-derived mesenchymal stem cells. FEBS Lett 582: 2615-2619.
112. Liu W, Frank JA. 2009. Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol 70: 258-264.
113. Liu L, Zhu X-D, Wang W-Q, Shen Y, Qin Y, Ren Z-G, Sun H-C, Tang Z-Y. 2010. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 16: 2740-2750.
114. Lu X, Kang Y. 2010. Hypoxia and hypoxia-inducible factors: Master regulators of metastasis. Clin Cancer Res 16: 5928-5935.
115. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, et al. 2013. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23: 171-185.
116. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z. 2011. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 6: e29170.
117. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. 1997. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403-407.
118. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. 2007. Tumor-specific positron emission tomography imaging in patients: [18F] Fluorodeoxyglucose and beyond. Clin Cancer Res 13: 3460-3469.
119. Mao P, Joshi K, Li J, Kim S-H, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, et al. 2013a. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 110: 8644-8649.
120. Mao Q, Zhang Y, Fu X, Xue J, Guo W, Meng M, Zhou Z, Mo X, Lu Y. 2013b. A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. J Cancer Res Clin Oncol 139: 211-222.
121. Marie-Egyptienne DT, Lohse I, Hill RP. 2013. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: Potential role of hypoxia. Cancer Lett 341: 63-72.
122. Martin Rodriguez-Porcel JC, Wu SSG. 2009. Molecular imaging of stem cells. In: StemBook, M elton D, editor. Harvard University: Harvard Stem Cell Institute.
123. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CMA, Hubaud A, Stadler B, Choi M, Bar M, et al. 2011. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-4652.
124. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. 1997. Hypoxiainducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109.
125. Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11: 293-299.
126. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, Omura M, Odagiri K, Tohnai I, Inoue T, et al. 2011. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: A pilot study. Ann Nucl Med 25: 339-345.
127. Minet E, Michel G, Mottet D, Raes M, Michiels C. 2001. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Rad Biol Med 31: 847-855.
128. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J. 2005. Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
129. Moeller BJ, Cao Y, Li CY, Dewhirst MW. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.
130. Moeller BJ, Richardson RA, Dewhirst MW. 2007. Hypoxia and radiotherapy: Opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26: 241-248.
131. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. 2010. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 7: 150-161.
132. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, et al. 2012. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 105: 14-20.
133. Moustakas A, Heldin C-H. 2007. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520.
134. Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, Park S-Y, Lu J, Protopopov A, Silberstein LE. 2013. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment . Nat Cell Biol 15: 533-543.
135. ODonoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, et al. 2005. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61: 1493-1502.
136. Overgaard J. 2007. Hypoxic radiosensitization: Adored and Ignored. J Clin Oncol 25: 4066-4074.
137. Padua D, Zhang XH-F, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J. 2008. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77.
138. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. 2010. Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
139. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. 2006. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187-197.
140. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, et al. 2006. Highly purified CD44 prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
141. Peinado H, Olmeda D, Cano A. 2007. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428.
142. Peng J, Zhang L, Drysdale L, Fong G-H. 2000. The transcription factor EPAS-1/hypoxia-inducible factor 2 α plays an important role in vascular remodeling. Proc Natl Acad Sci 97: 8386-8391.
143. Pires IM, Bencokova Z, Milani M, Folkes LK, Li J-L, Stratford MR, Harris AL, Hammond EM. 2010. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 70: 925-935.
144. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F, Wion D. 2007. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 258: 286-290.
145. Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P, Dissmann PD, Fischer H, Bares R, Becker HD, et al. 1999. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 26: 95-109.
146. Piert M, Machulla H-J, Picchio M, Reischl G, Ziegler S, Kumar P, Wester H-J, Beck R, McEwan AJB, Wiebe LI, et al. 2005. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46: 106-113.
147. Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. 2009. Initial results of hypoxia imaging using 1-alpha-D:-(5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging 36: 1565-1573.
148. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. 2007. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978.
149. Psaila B, Lyden D. 2009. The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 9: 285-293.
150. Rajendran JG, Schwartz DL, OSullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA. 2006. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12: 5435-5441.
151. Rankin EB, Giaccia AJ. 2008. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685.
152. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J. 1999. p42/p44 Mitogen-activated protein kinases phosphorylate hypoxia-inducible Factor 1 α (HIF-1 α ) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637.
153. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ, Trans-Tasman Radiation Oncology Group Study 98.02. 2006. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24: 2098-2104.
154. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. 2008. NF-κ B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1 α . Nature 453: 807-811.
155. Ross AC. 2012. Vitamin A and retinoic acid in T cell-related immunity. Am J Clin Nutr 96: 1166S-1172S.
156. Ryan HE, Lo J, Johnson RS. 1998. HIF-1 α is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015.
157. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS. 2000. Hypoxia-inducible Factor-1 α is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015.
158. Salceda S, Caro J. 1997. Hypoxia-inducible Factor 1 α (HIF-1 α ) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redoxinduced changes. J Biol Chem 272: 22642-22647.
159. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. 2008. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with Bevacizumab and Irinotecan. J Clin Oncol 26: 271-278.
160. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T, et al. 2012. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med 1: 811-824.
161. Schofield R. 1978. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4: 7-25.
162. Sears R, Leone G, DeGregori J, Nevins JR. 1999. Ras enhances Myc protein stability. Mol Cell 3: 169-179.
163. Semenza GL. 1998. Hypoxia-inducible factor 1: Master regulator of O 2 homeostasis. Curr Opin Genet Dev 8: 588-594.
164. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
165. Semenza GL. 2010. HIF-1: Upstream and downstream of cancer metabolism . Curr Opin Genet Dev 20: 51-56.
166. Semenza GL. 2013. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32: 4057-4063.
167. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. 1991. Hypoxiainducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 88: 5680-5684.
168. Shigdar S, Lin J, Li Y, Yang CJ, Wei M, Zhus Y, Liu H, Duan W. 2012. Cancer stem cell targeting: The next generation of cancer therapy and molecular imaging. Ther Deliv 3: 227-244.
169. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432: 396-401.
170. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI, Tumor and Angiogenesis Research Group. 2002. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95: 1055-1063.
171. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. 2005. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 65: 7259-7266.
172. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. 2000. The Kaposi s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible Factor 1 α . Cancer Res 60: 4873-4880.
173. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al. 2009. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28: 3949-3959.
174. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. 2003. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311.
175. Sun N, Lee A, Wu JC. 2009. Long term non-invasive imaging of embryonic stem cells using reporter genes. Nat Protoc 4: 1192-1201.
176. Swietach P, Vaughan-Jones RD, Harris AL. 2007. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26: 299-310.
177. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. The expression and distribution of the hypoxia-inducible Factors HIF-1 α and HIF-2 α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421.
178. Tammela T, Alitalo K. 2010. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
179. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, et al. 2003. Hypoxia-inducible factor-1 α polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24: 1779-1783.
180. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
181. Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, Tomlins SA, Kristiansen G, Theodorescu D. 2012. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res 72: 5600-5612.
182. Thomlinson RH, Gray LH. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy . Br J Cancer 9: 539-549.
183. Thorwarth D, Eschmann S-M, Scheiderbauer J, Paulsen F, Alber M. 2005. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5: 152.
184. Thorwarth D, Mönnich D, Zips D. 2013. Methodological aspects on hypoxia PET acquisition and image processing. Chem Biol 57: 235-243.
185. Turcotte S, Desrosiers RR, Béliveau R. 2003. HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 116: 2247-2260.
186. Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM. 2013. Comparison of 18Ffluoroazomycin- arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer. J Nucl Med 54: 1106-1112.
187. Van Uden P, Kenneth NS, Rocha S. 2008. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412: 477-484.
188. Vaupel P, Mayer A. 2007. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239.
189. Vaupel P, Mayer A, Höckel M. 2004. Tumor hypoxia and malignant progression . Methods Enzym 381: 335-354.
190. Vaupel P, Höckel M, Mayer A. 2007. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9: 1221-1235.
191. Vazquez F, Lim J-H, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, et al. 2013. PGC1? expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23: 287-301.
192. Visvader JE, Lindeman GJ. 2008. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
193. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
194. Wang GL, Semenza GL. 1993. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268: 21513-21518.
195. Wang GL, Jiang BH, Rue EA, Semenza GL. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci 92: 5510-5514.
196. Warburg O. 1956. On respiratory impairment in cancer cells. Science 124: 269-270.
197. Warburg O. 1925.über den Stoffwechsel der Carcinomzelle. Klin. Wochenschr 4: 534-536.
198. Weng AP, Aster JC. 2004. Multiple niches for Notch in cancer: Context is everything. Curr Opin Genet Dev 14: 48-54.
199. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, et al. 2006. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20: 2096-2109.
200. Wilson A, Radtke F. 2006. Multiple functions of Notch signaling in selfrenewing organs and cancer. FEBS Lett 580: 2860-2868.
201. Wilson A, Trumpp A. 2006. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6: 93-106.
202. Wilson WR, Hay MP. 2011. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
203. Wilson A, Oser GM, Jaworski M, Blanco-Bose WE, Laurenti E, Adolphe C, Essers MA, Macdonald HR, Trumpp A. 2007. Dormant and selfrenewing hematopoietic stem cells and their niches. Ann NY Acad Sci 1106: 64-75.
204. Winter SC, Shah KA, Han C, Campo L, Turley H, Leek R, Corbridge RJ, Cox GJ, Harris AL. 2006. The relation between hypoxia-inducible factor (HIF)-1 α and HIF-2 α expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107: 757-766.
205. Wong CC-L, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong C-M, Khoo U-S, Ng IO-L, et al. 2011. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation . Proc Natl Acad Sci USA 108: 16369-16374.
206. Xia T, Jiang H, Li C, Tian M, Zhang H. 2012. Molecular imaging in tracking tumor stem-like cells. J Biomed Biotechnol 2012: 420364.
207. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J. 2013. NF-kB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 4: 2299.
208. Yang M-H, Wu K-J. 2008. TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle 7: 2090-2096.
209. Yin T, Li L. 2006. The stem cell niches in bone. J Clin Invest 116: 1195-1201.
210. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. 1998. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275: L818-826.
211. Yu Q, Toole BP, Stamenkovic I. 1997. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186: 1985-1996.
212. Zahra MA, Tan LT, Priest AN, Graves MJ, Arends M, Crawford RAF, Brenton JD, Lomas DJ, Sala E. 2009. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74: 766-773.
213. Zhang J, Ney PA. 2009. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ 16: 939-946.
214. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. 2008. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892-10903.
215. Zhong H, Marzo AMD, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. 1999. Overexpression of hypoxia-inducible Factor 1 α in common human cancers and their metastases. Cancer Res 59: 5830-5835.
216. Zhu P, Tan MJ, Huang R-L, Tan CK, Chong HC, Pal M, Lam CRI, Boukamp P, Pan JY, Tan SH, et al. 2011. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell 19: 401-415.
217. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M. 2012. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 105: 21-28.
218. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, et al. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396.